MX2020005692A - Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario. - Google Patents

Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.

Info

Publication number
MX2020005692A
MX2020005692A MX2020005692A MX2020005692A MX2020005692A MX 2020005692 A MX2020005692 A MX 2020005692A MX 2020005692 A MX2020005692 A MX 2020005692A MX 2020005692 A MX2020005692 A MX 2020005692A MX 2020005692 A MX2020005692 A MX 2020005692A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
immune checkpoint
checkpoint inhibitor
antitumor effect
enhancing antitumor
Prior art date
Application number
MX2020005692A
Other languages
English (en)
Inventor
Tohru Tanaka
Hidenori Ito
Ko Rii
Original Assignee
Sbi Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Pharmaceuticals Co Ltd filed Critical Sbi Pharmaceuticals Co Ltd
Publication of MX2020005692A publication Critical patent/MX2020005692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

El objeto de la invención es proporcionar una composición farmacéutica para potenciar el efecto antitumoral mediante un inhibidor del punto de control inmunitario. Se proporciona una composición farmacéutica para potenciar el efecto antitumoral mediante un inhibidor del punto de control inmunitario que comprende ácidos 5-aminolevulínicos (ALAs) como ingrediente activo.
MX2020005692A 2017-12-01 2018-11-28 Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario. MX2020005692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017231449 2017-12-01
PCT/JP2018/043704 WO2019107389A1 (ja) 2017-12-01 2018-11-28 免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物

Publications (1)

Publication Number Publication Date
MX2020005692A true MX2020005692A (es) 2020-09-25

Family

ID=66665041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005692A MX2020005692A (es) 2017-12-01 2018-11-28 Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.

Country Status (14)

Country Link
US (2) US11266619B2 (es)
EP (1) EP3673904B1 (es)
JP (2) JP6617220B2 (es)
KR (1) KR102214029B1 (es)
CN (2) CN118557559A (es)
AU (1) AU2018377785B2 (es)
BR (1) BR112020010839A2 (es)
CA (1) CA3079496C (es)
MX (1) MX2020005692A (es)
MY (1) MY181242A (es)
PH (1) PH12020550124B1 (es)
RU (1) RU2760132C1 (es)
TW (1) TWI878223B (es)
WO (1) WO2019107389A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005692A (es) * 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
JP2025024778A (ja) 2023-08-08 2025-02-21 学校法人帝京大学 油脂を過剰蓄積する油脂生産酵母変異株

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5380436A (en) 1976-12-27 1978-07-15 Isuzu Motors Ltd Adhesive comosition and method of making same
JPH10110107A (ja) 1996-10-04 1998-04-28 Fuji Photo Film Co Ltd 新規メチン化合物及び該化合物を含むハロゲン化銀写真感光材料
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
CN106692122A (zh) * 2008-10-27 2017-05-24 思佰益药业股份有限公司 以5‑氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
AU2010257752B2 (en) 2009-06-11 2015-04-09 Photocure Asa Solid compositions comprising 5-aminolevulinic acid
JP5611548B2 (ja) * 2009-07-08 2014-10-22 Ｓｂｉファーマ株式会社 ５−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤
JP2012012305A (ja) * 2010-06-29 2012-01-19 Kanazawa Univ 抗がん剤の作用増強剤
CN110339207B (zh) 2011-10-12 2022-08-05 思佰益药业股份有限公司 抗癌剂的副作用的预防剂和/或治疗剂
WO2015129535A1 (ja) 2014-02-25 2015-09-03 学校法人産業医科大学 腫瘍免疫誘導用組成物
WO2016187122A1 (en) * 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
MX2020005692A (es) * 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.

Also Published As

Publication number Publication date
EP3673904A1 (en) 2020-07-01
PH12020550124B1 (en) 2024-05-24
BR112020010839A2 (pt) 2020-09-15
EP3673904A4 (en) 2021-06-09
US20220249417A1 (en) 2022-08-11
AU2018377785B2 (en) 2020-10-01
RU2760132C1 (ru) 2021-11-22
JPWO2019107389A1 (ja) 2019-12-12
KR20200085346A (ko) 2020-07-14
EP3673904C0 (en) 2024-10-23
CA3079496C (en) 2021-06-01
US11266619B2 (en) 2022-03-08
NZ765602A (en) 2020-11-27
CN118557559A (zh) 2024-08-30
AU2018377785A1 (en) 2020-07-09
KR102214029B1 (ko) 2021-02-08
JP6617220B2 (ja) 2019-12-11
CN111417390A (zh) 2020-07-14
PH12020550124A1 (en) 2021-02-08
US20200297674A1 (en) 2020-09-24
TW202019488A (zh) 2020-06-01
JP2019182882A (ja) 2019-10-24
WO2019107389A1 (ja) 2019-06-06
CA3079496A1 (en) 2019-06-06
TWI878223B (zh) 2025-04-01
EP3673904B1 (en) 2024-10-23
US12558332B2 (en) 2026-02-24
MY181242A (en) 2020-12-21

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
MY207356A (en) Nrf2 regulators
MX2022005182A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX2017014035A (es) Formas solidas novedosas.
PH12016500225B1 (en) Novel quinoline-substituted compound
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX364400B (es) Compuestos de tetraciclina.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
PH12020550124A1 (en) Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
MX2016005348A (es) Compuestos novedosos.
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
NZ702684A (en) Hexadepsipeptide analogues as anticancer compounds
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
MY189798A (en) Novel biphenyl compound or salt thereof
PH12019501686A1 (en) Improved process
MX2019012380A (es) Cristales de compuesto piranodipiridinico.
IN2013MU02279A (es)